BR112023001048A2 - Agonista de ppar-delta cristalino - Google Patents

Agonista de ppar-delta cristalino

Info

Publication number
BR112023001048A2
BR112023001048A2 BR112023001048A BR112023001048A BR112023001048A2 BR 112023001048 A2 BR112023001048 A2 BR 112023001048A2 BR 112023001048 A BR112023001048 A BR 112023001048A BR 112023001048 A BR112023001048 A BR 112023001048A BR 112023001048 A2 BR112023001048 A2 BR 112023001048A2
Authority
BR
Brazil
Prior art keywords
crystalline
ppar
delta agonist
agonist
delta
Prior art date
Application number
BR112023001048A
Other languages
English (en)
Inventor
DEL RIO GANCEDO Susana
Suleiman Osama
Sharp Emma
Balogh Cristina
Lee Rachael
Macrae Julie
Feeder Neil
Original Assignee
Reneo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneo Pharmaceuticals Inc filed Critical Reneo Pharmaceuticals Inc
Publication of BR112023001048A2 publication Critical patent/BR112023001048A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

AGONISTA DE PPAR-DELTA CRISTALINO. É descrito nesse documento (E)-2-(4-((3-(4-fluorofenil)-3-(4-(3-morfolinoprop-1-in-1-il)fenil)alil)óxi)-2-metilfenóxi)acetato de sódio cristalino, usos de tal material cristalino na preparação de composições farmacêuticas para o tratamento de doenças ou condições que se beneficiariam da administração com um composto agonista de PPARdelta.
BR112023001048A 2020-07-22 2021-07-20 Agonista de ppar-delta cristalino BR112023001048A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055235P 2020-07-22 2020-07-22
US202063118431P 2020-11-25 2020-11-25
PCT/US2021/042412 WO2022020376A1 (en) 2020-07-22 2021-07-20 Crystalline ppar-delta agonist

Publications (1)

Publication Number Publication Date
BR112023001048A2 true BR112023001048A2 (pt) 2023-04-04

Family

ID=79687855

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001048A BR112023001048A2 (pt) 2020-07-22 2021-07-20 Agonista de ppar-delta cristalino

Country Status (12)

Country Link
US (3) US11267795B2 (pt)
EP (1) EP4185572A1 (pt)
JP (1) JP2023534835A (pt)
KR (1) KR20230054373A (pt)
CN (1) CN116249695A (pt)
AU (1) AU2021312855A1 (pt)
BR (1) BR112023001048A2 (pt)
CA (1) CA3185909A1 (pt)
IL (1) IL300000A (pt)
MX (1) MX2023001001A (pt)
TW (1) TW202219038A (pt)
WO (1) WO2022020376A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020376A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist
WO2023147309A1 (en) * 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331336A1 (fr) 1975-11-14 1977-06-10 Rolland Sa A Acides oxy-4,4' bis(phenoxy-2 alcanocarboxyliques), leurs derives et leur application comme medicament
US4920132A (en) 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5773469A (en) 1996-06-18 1998-06-30 Ortho Pharmaceutical Corporation Diaryl antimicrobial agents
JP2002542218A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
AU3507700A (en) 1999-06-01 2000-12-18 University Of Texas Southwestern Medical Center, The Method of treating hair loss using diphenylether derivatives
MXPA02007295A (es) 2000-01-28 2002-11-29 Novo Nordisk As Derivados de acido propionico alquinilsubstituidos y su uso contra diabetes y obesidad.
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
JP2003520838A (ja) 2000-01-28 2003-07-08 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造および使用。
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
WO2001079150A1 (en) 2000-04-17 2001-10-25 Novo Nordisk A/S New compounds, their preparation and use
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
RU2004105956A (ru) * 2001-07-30 2005-03-27 Ново Нордиск А/С (DK) Новые производные винилкарбоновых кислот и их применение в качестве антидиабетических средств и т.п.
EP1414785A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
CA2460313C (en) 2001-09-14 2011-03-08 Tularik Inc. Bisphenylsulfanyl and sulphonate compounds and use thereof for elevating hdl cholesterol levels
JP2005505616A (ja) 2001-10-17 2005-02-24 ノボ　ノルディスク　アクティーゼルスカブ ジカルボン酸誘導体、それらの調製、並びに治療上の用途
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
EP1537076A1 (en) 2002-09-05 2005-06-08 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
JP4708184B2 (ja) 2002-10-28 2011-06-22 ハイ ポイント ファーマシューティカルズ，エルエルシー 新規の化合物、それらの調製及び使用
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
PL376704A1 (pl) * 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR
EP1745002B1 (en) 2004-05-05 2010-11-03 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
WO2005105735A1 (en) * 2004-05-05 2005-11-10 Novo Nordisk A/S Phenoxyacetic acid derivatives as ppar agonists
MX2007016374A (es) 2005-06-30 2008-03-05 Novo Nordisk As Acidos fenoxiaceticos como activadores ppar delta.
EA015717B1 (ru) 2005-12-22 2011-10-31 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US20100197950A1 (en) 2006-06-08 2010-08-05 Kaare Gyberg Rasmussen Process for preparing phenoxy acetic acid derivatives
US9487493B2 (en) 2013-09-09 2016-11-08 Vtv Therapeutics Llc Use of a PPAR-delta agonist for treating muscle atrophy
US9669288B2 (en) 2014-11-18 2017-06-06 Ags, Llc Method, apparatus, clustered devices, and computer readable storage for conducting a wagering game
WO2022020376A1 (en) 2020-07-22 2022-01-27 Reneo Pharmaceuticals, Inc. Crystalline ppar-delta agonist

Also Published As

Publication number Publication date
CN116249695A (zh) 2023-06-09
IL300000A (en) 2023-03-01
CA3185909A1 (en) 2022-01-27
JP2023534835A (ja) 2023-08-14
US20220135532A1 (en) 2022-05-05
WO2022020376A1 (en) 2022-01-27
AU2021312855A1 (en) 2023-03-09
US20220024888A1 (en) 2022-01-27
US20240002356A1 (en) 2024-01-04
KR20230054373A (ko) 2023-04-24
TW202219038A (zh) 2022-05-16
US11267795B2 (en) 2022-03-08
EP4185572A1 (en) 2023-05-31
US11713301B2 (en) 2023-08-01
MX2023001001A (es) 2023-03-01

Similar Documents

Publication Publication Date Title
BR112023001048A2 (pt) Agonista de ppar-delta cristalino
BR112022004495A2 (pt) Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
BRPI0610907A2 (pt) composto ou precursores hidrolisÁveis in vivo ou sal farmaceuticamente aceitÁvel do mesmo, mÉtodos de tratamento ou profilaxia de uma doenÇa ou condiÇço na qual a modulaÇço do receptor de mch1 É benÉfica e de tratamento ou profilaxia de doenÇas, composiÇço farmacÊutica, e, uso de um composto
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
BR112019025214A2 (pt) Composição farmacêutica sólida administrável por via oral, uso da composição farmacêutica, processo para a preparação de composições farmacêuticas, e, método de tratamento de um paciente que sofre de condições patológicas
MX2015013893A (es) Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo.
MX2021006969A (es) Ligante peptidico.
PE20191205A1 (es) Composiciones farmaceuticas que contienen insulina
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022021748A2 (pt) Compostos e composições para inibir a atividade de hif2a e seus métodos de uso
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
MA39443A1 (fr) Nouvelle formulation de méloxicam
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BRPI0511951A (pt) compostos, uso de um composto, e composição farmacêutica
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
BR112021018578A2 (pt) Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
AR060526A1 (es) Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6